公开(公告)号：US20180251445A1

公开(公告)日：2018-09-06

申请号：US15971330

申请日：2018-05-04

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Martin Teall

IPC: C07D401/12 ,  A61K31/454

CPC classification number: C07D401/12 ,  A61K31/454

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R1, R2, R3, R4 and R5 are as defined in the specification, compositions containing them and their use in therapy.

公开(公告)号：US20180009780A1

公开(公告)日：2018-01-11

申请号：US15702100

申请日：2017-09-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Sarah Bousba ,  Anne Goldby ,  Kerry Jenkins ,  Natasha Kinsella ,  Martin Teall

IPC: C07D401/06 ,  C07D401/14 ,  A61K31/55 ,  A61K31/501 ,  A61K31/4545 ,  C07D403/06 ,  A61K31/454

CPC classification number: C07D401/06 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/501 ,  A61K31/55 ,  C07D401/14 ,  C07D403/06

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R1, R2, R3 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions N containing them and their use in therapy.

公开(公告)号：US11465994B2

公开(公告)日：2022-10-11

申请号：US16461427

申请日：2017-11-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Martin Teall ,  Kathryn White ,  Stephen Mack ,  Gemma Liwicki ,  Anne Stephenson ,  Louise Dickson

IPC: C07D413/04 ,  C07D311/68 ,  C07D401/12 ,  C07D401/14 ,  C07D407/04

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Z, R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy. The present invention further provides methods of treating at least one disease, disorder, or condition associated with the glutamatergic and GABAergic signalling pathways regulated in full or in part by metabotropic glutamate receptor 7 (mGluR7) by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject. The compound may be a selective agonist of mGluR7, which modulates the release of at least one neurotransmitter in the subject.

公开(公告)号：US10544126B2

公开(公告)日：2020-01-28

申请号：US16194762

申请日：2018-11-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Colm Carroll ,  Anne Goldby ,  Martin Teall

IPC: C07D401/12 ,  A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  C07D211/96 ,  C07D401/14

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.

公开(公告)号：US10308635B2

公开(公告)日：2019-06-04

申请号：US15971330

申请日：2018-05-04

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Martin Teall

IPC: C07D401/12 ,  A61K31/454

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R1, R2, R3, R4 and R5 are as defined in the specification, compositions containing them and their use in therapy.

公开(公告)号：US10208016B2

公开(公告)日：2019-02-19

申请号：US14893148

申请日：2014-06-20

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Martin Teall

IPC: C07D401/12 ,  A61K31/454

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R1, R2, R3, R4 and R5 are as defined in the specification, compositions containing them and their use in therapy.

公开(公告)号：US20190031599A1

公开(公告)日：2019-01-31

申请号：US16072296

申请日：2017-01-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Anne Goldby ,  Gemma Liwicki ,  Stephen Mack ,  Martin Teall ,  Katy White

IPC: C07C233/41 ,  C07C233/23 ,  A61P25/30 ,  A61P25/18 ,  A61P27/16

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

公开(公告)号：US10167273B2

公开(公告)日：2019-01-01

申请号：US15262436

申请日：2016-09-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Colm Carroll ,  Anne Goldby ,  Martin Teall

IPC: C07D401/12 ,  A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  C07D211/96 ,  C07D401/14

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.

公开(公告)号：US20170340621A1

公开(公告)日：2017-11-30

申请号：US15525417

申请日：2015-11-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Philip Mitchell ,  Martin Teall

IPC: A61K31/454

CPC classification number: A61K31/454 ,  C07D401/12

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, n, W, X, Y, Z, R1, R2, R3, R4 and R5 are as defined in the specification for use in treating irritable bowel syndrome or inflammatory bowel disease.

公开(公告)号：US20230073334A1

公开(公告)日：2023-03-09

申请号：US17962781

申请日：2022-10-10

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Colm Carroll ,  Anne Goldby ,  Martin Teall

IPC: C07D401/12 ,  A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  C07D211/96 ,  C07D401/14

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.